Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.56 |
| ▸ | ERN1 | O75460 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MIF | P14174 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30489914 | 1.00 | CYP2A6 (0.56) | CYP2A6ERN1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL14156856 | 0.82 | CYP2A6 (0.62) | CYP2A6ERN1ALDH1A1MEN1KMT2A | |
| SCHEMBL20954493 | 0.78 | CYP2A6 (0.56) | CYP2A6ERN1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL10692786 | 0.78 | CYP2A6 (0.56) | CYP2A6ERN1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL21828957 | 0.78 | CYP2A6 (0.56) | CYP2A6ERN1ALDH1A1MEN1KMT2A | |
| SCHEMBL20954351 | 0.77 | CYP2A6 (0.51) | CYP2A6ERN1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL25032981 | 0.76 | CYP2A6 (0.55) | CYP2A6ERN1ALDH1A1MEN1KMT2A | |
| SCHEMBL15595312 | 0.76 | RXRA (0.49) | ALDH1A1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL20954531 | 0.74 | CYP2A6 (0.51) | CYP2A6ERN1ALDH1A1HTTMEN1 | |
| SCHEMBL15573987 | 0.74 | AKR1A1 (0.32) | CYP2A6ERN1ALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111491935-B | Novel analogs as modulators of androgen and glucocorticoid receptors | 昂科斯特拉公司 | 2023-08-22 | — | — | CN | disclosed |
| EP-3707143-B9 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | ONCOSTELLAE S L (ES) | 2023-04-12 | — | — | EP | disclosed |
| EP-3707143-B1 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | ONCOSTELLAE S L (ES) | 2022-12-28 | — | — | EP | disclosed |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. (US) | 2022-12-15 | — | — | US | disclosed |
| US-11453660-B2 | Androgen receptor and glucocorticoid receptor modulators | ONCOSTELLAE, S.L. | 2022-09-27 | — | — | US | disclosed |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | Janssen Biopharma, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | Janssen Biopharma, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200325123-A1 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | ONCOSTELLAE, S.L. (ES) | 2020-10-15 | — | — | US | disclosed |
| EP-3707143-A1 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | Oncostellae, S.L. (ES) | 2020-09-16 | — | — | EP | disclosed |
| US-20070191459-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191453-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | SMITH-SWINTOSKY VIRGINIA L | 2007-08-16 | — | — | US | disclosed |
| US-20070191451-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS | SMITH-SWINTOSKY VIRGINIA L | 2007-08-16 | — | — | US | disclosed |
| US-20070191452-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | SMITH-SWINTOSKY VIRGINIA L | 2007-08-16 | — | — | US | disclosed |
| EP-1794143-A1 | NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-13 | — | — | EP | disclosed |
| US-20060276528-A1 | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | ABDEL-MAGID AHMED F | 2006-12-07 | — | — | US | disclosed |
| US-20060270856-A1 | Process for preparation of sulfamide derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2006-11-30 | — | — | US | disclosed |
| WO-2006127184-A1 | PROCESS FOR PREPARATION OF SULFAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006023861-A1 | NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-02 | — | — | WO | disclosed |
| US-20060047001-A1 | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | JANSSEN PHARMACAEUTICA N.V. (BE) | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | CYP2A6 4442/4885ERN1 1684/4885ALDH1A1 3714/4885 |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | MAVS, SARS1, ZC3HAV1 | CYP2A6 4442/4885ERN1 1684/4885ALDH1A1 3714/4885 |
| US-20060276528-A1 | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | GABRA5, SULT2A1, SYNGR2 | CYP2A6 135/4885ERN1 4413/4885ALDH1A1 1128/4885 |
| US-20070191451-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS | NLN, CTSA, SMN1; SMN2 | CYP2A6 2859/4885ERN1 3139/4885ALDH1A1 470/4885 |
| US-20060047001-A1 | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | GABRE, GABRB2, GABRA2 | CYP2A6 223/4885ERN1 4454/4885ALDH1A1 855/4885 |
| US-20070191459-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels | LIPC, GPR119, APOB | CYP2A6 484/4885ERN1 4588/4885ALDH1A1 694/4885 |
| US-20070191452-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | OPRL1, SULT2A1, OPRK1 | CYP2A6 326/4885ERN1 4693/4885ALDH1A1 209/4885 |
| US-20200325123-A1 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | NR5A1, AR, NR3C1 | CYP2A6 511/4885ERN1 4241/4885ALDH1A1 1672/4885 |
| US-20060270856-A1 | Process for preparation of sulfamide derivatives | STS, SULT2A1, SULT1A1 | CYP2A6 852/4885ERN1 3664/4885ALDH1A1 1607/4885 |
| US-11453660-B2 | Androgen receptor and glucocorticoid receptor modulators | AR, NR5A1, NR3C1 | CYP2A6 445/4885ERN1 4311/4885ALDH1A1 1496/4885 |
| US-20070191453-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | SULT2A1, SULT1A1, STS | CYP2A6 146/4885ERN1 4015/4885ALDH1A1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.